Dabrafenib (Tafinlar) with trametinib (Mekinist) for BRAF V600 mutation positive melanoma – adjuvant therapy
NIHR HSRIC
Record ID 32016001001
English
Authors' objectives:
Dabrafenib and trametinib are two drugs that are taken together to treat melanoma that has been caused by a mutation called BRAF V600. Melanoma is a type of skin cancer that usually develops from abnormal moles. Dabrafenib and trametinib are given as two separate tablets that are taken together each day. They target the BRAF V600 mutation to stop the tumours growing. This may offer a new treatment option for patients who are at risk of their melanoma returning, despite having already had surgery to remove the disease.
Details
Project Status:
Completed
URL for project:
http://www.hsric.nihr.ac.uk/topics/dabrafenib-tafinlar-with-trametinib-mekinist-for-braf-v600-mutation-positive-melanoma/
Year Published:
2016
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Humans
- Melanoma
- Mutation
- Oximes
- Pyridones
- Pyrimidinones
Contact
Organisation Name:
NIHR Horizon Scanning Centre
Contact Address:
The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom. Tel: +44 121 414 7831, Fax: +44 121 2269
Contact Name:
c.packer@bham.ac.uk
Contact Email:
c.packer@bham.ac.uk
Copyright:
NIHR Horizon Scanning Research&Intelligence Centre (NIHR HSRIC)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.